# ATP2A1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - ATP2A1 encodes SERCA1, a critical sarcoplasmic reticulum calcium ATPase essential for fast-twitch skeletal muscle relaxation by actively transporting Ca²⁺ from the cytosol into the SR lumen. - Pathogenic variants in ATP2A1 cause Brody disease, an autosomal recessive myopathy characterized by exercise-induced muscle stiffness and delayed relaxation, with over 30 reported mutations affecting various domains of the protein. - Congenital pseudomyotonia in cattle, caused by specific ATP2A1 mutations like Arg164Trp, serves as a valuable large-animal model for studying Brody disease pathogenesis, particularly concerning protein misfolding and ubiquitin-proteasome system degradation. - SERCA1 function is regulated by protein interactions, notably with sarcolipin (SLN), and its expression is tightly controlled by muscle-specific transcription factors such as MyoD and Ebf, ensuring fiber-type specificity. - Emerging evidence implicates ATP2A1 in broader biological contexts, including cancer biology, metabolic disorders, and cognitive function, suggesting potential therapeutic targets beyond neuromuscular diseases. - Investigational therapies for ATP2A1-related disorders include drug repurposing (e.g., CFTR corrector C17 for misfolding mutations) and targeting protein degradation pathways, with ongoing research exploring its role in host-pathogen interactions. --- ## Executive Summary & Key Metadata The ATP2A1 gene encodes the sarco(endo)plasmic reticulum calcium ATPase isoform 1 (SERCA1), a P-type ATPase that catalyzes the ATP-dependent transport of Ca²⁺ from the cytosol into the lumen of the sarcoplasmic reticulum (SR) in fast-twitch skeletal muscle fibers. This transport is fundamental to muscle relaxation following contraction, as it re-sequesters cytosolic Ca²⁺ to terminate the contractile signal. Pathogenic variants in ATP2A1 cause Brody disease, an autosomal recessive myopathy characterized by exercise-induced muscle stiffness and delayed relaxation. The gene has also been implicated in congenital pseudomyotonia in cattle, serving as a valuable large-animal model for the human condition. Beyond its canonical role in muscle physiology, emerging evidence links ATP2A1 expression to cancer biology, metabolic disorders, and cognitive function, expanding its clinical relevance beyond the neuromuscular domain. | **Attribute** | **Value** | |---|---| | HGNC Symbol | ATP2A1 | | UniProt Accession | O14983 | | Representative PDB ID | 1SU4 (SERCA1a E2·MgF₄²⁻ state), 1T5S, 2OA0, 3AR4, 4H1B | | Chromosomal Locus | 16p12.1 (human); 7q26 (mouse); 3 (pig); 19 (cattle) | | Primary Molecular Function | ATP-dependent Ca²⁺:H⁺ antiporter activity; sarcoplasmic reticulum calcium ion transmembrane transport | | Disease & Pathology Associations | Brody disease (OMIM #601003); congenital pseudomyotonia (cattle); Brody syndrome; potential roles in cancer, metabolic syndrome, and cognitive traits | | Expression Pattern | Predominantly fast-twitch (type II) skeletal muscle fibers; low-level expression in other tissues | | Protein Length | 994 amino acids (SERCA1a); 1001 amino acids (SERCA1b, alternative C-terminus) | | Topology | 10 transmembrane helices (M1–M10); 3 cytoplasmic domains (A, N, P) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human ATP2A1 gene is located on the short arm of chromosome 16 at band 16p12.1, a region that has been associated with several genetic disorders, including distal 16p11.2 microdeletion syndrome [1]. The gene spans approximately 26 kilobases of genomic DNA and contains 23 exons, with the translation initiation codon located in exon 1 and the termination codon in exon 23 [2]. The genomic organization is highly conserved across mammals; the porcine ATP2A1 gene maps to chromosome 3, the bovine gene to chromosome 19, and the mouse gene to chromosome 7 [3, 4, 5]. The promoter region of ATP2A1 lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for muscle-specific transcription factors. Functional characterization has identified critical roles for E-box elements (CANNTG motifs) that serve as binding sites for basic helix-loop-helix (bHLH) myogenic regulatory factors, including MyoD, Myf5, and myogenin. The transcription factor Ebf (early B-cell factor) cooperates with MyoD to regulate ATP2A1 expression during skeletal muscle development, and this cooperation is essential for proper muscle relaxation function [6]. Chromatin immunoprecipitation studies have demonstrated direct binding of Ebf proteins to regulatory regions of the Atp2a1 gene in mouse muscle, and genetic ablation of Ebf factors leads to reduced Atp2a1 expression and impaired muscle relaxation [6]. ### 1.2 Alternative Splicing and Isoform Diversity Alternative splicing of ATP2A1 produces two major isoforms, SERCA1a and SERCA1b, which differ only in their C-terminal regions. The SERCA1a isoform (994 amino acids) is the adult form, expressed predominantly in adult fast-twitch skeletal muscle. The SERCA1b isoform (1001 amino acids) contains an additional seven amino acids at the C-terminus and is expressed primarily during fetal and neonatal development [2]. The alternative splicing event involves exon 22, which is included in SERCA1b but excluded in SERCA1a, resulting in a frameshift that alters the C-terminal coding sequence. The developmental switch from SERCA1b to SERCA1a is regulated by the RNA-binding protein muscleblind-like 1 (MBNL1). In myotonic dystrophy type 1 (DM1), expanded CUG repeats in the DMPK gene sequester MBNL1, leading to mis-splicing of ATP2A1 and retention of the fetal SERCA1b isoform in adult muscle [7, 8]. This mis-splicing contributes to the muscle pathophysiology observed in DM1 patients. Small molecules that rescue MBNL1 activity or directly target the mis-splicing event have been explored as therapeutic strategies. The dimeric form of 1,3-diaminoisoquinoline derivatives has been shown to rescue mis-splicing of Atp2a1 and Clcn1 genes in a DM1 mouse model, restoring normal muscle function [7]. ### 1.3 Regulatory Elements and Epigenetic Control The ATP2A1 gene is subject to complex epigenetic regulation. DNA methylation at CpG islands in the promoter region correlates with gene expression levels, and demethylation is associated with transcriptional activation during muscle differentiation. In the context of joint injury, epigenetic modifications at the HDAC4 locus have been shown to influence muscle plasticity, with downstream effects on ATP2A1 expression [9]. The HDAC4-mediated epigenetic memory of joint injury disrupts the normal expression of fast-twitch muscle genes, including ATP2A1, contributing to protracted muscle weakness and atrophy. Transcriptional regulation of ATP2A1 also involves the Six1 homeoprotein, which promotes the expression of fast-type muscle genes. Overexpression of Six1 in C2C12 myoblasts suppresses proliferation and enhances the expression of fast-type muscle genes, including ATP2A1, indicating a role for Six1 in establishing the fast-twitch muscle phenotype [10]. The coordinated action of MyoD, Ebf, and Six1 ensures precise temporal and spatial control of ATP2A1 expression during myogenesis. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Topology and Domain Organization The SERCA1 protein is a 110-kDa integral membrane protein with a well-characterized three-dimensional structure. High-resolution crystal structures have been solved for multiple conformational states, providing atomic-level insights into the catalytic cycle of Ca²⁺ transport [1SU4, 1T5S, 2OA0, 3AR4, 4H1B]. The protein consists of three cytoplasmic domains—the actuator (A) domain, the nucleotide-binding (N) domain, and the phosphorylation (P) domain—connected to ten transmembrane helices (M1–M10) that form the Ca²⁺ translocation pathway. The **A domain** (residues 1–50 and 120–238) is the smallest of the three cytoplasmic domains and undergoes large rotational movements during the catalytic cycle. It contains the actuator loop that interacts with the phosphorylation site and facilitates dephosphorylation. The **N domain** (residues 360–600) binds ATP and is connected to the P domain through a flexible hinge region. The **P domain** (residues 330–360 and 600–760) contains the conserved aspartate residue (Asp351 in human SERCA1) that undergoes transient phosphorylation during the reaction cycle. The **transmembrane domain** (residues 57–119, 239–329, 761–994) contains two Ca²⁺ binding sites (site I and site II) formed by residues from helices M4, M5, M6, and M8. ### 2.2 Ca²⁺ Binding Sites and Ion Translocation Pathway The two Ca²⁺ binding sites are located in the transmembrane region, approximately halfway through the membrane bilayer. Site I is formed by residues Asn768, Glu771, Thr799, Asp800, and Glu908, while site II involves residues Val304, Ala305, Ile307, Asn796, and Glu309. The binding of two Ca²⁺ ions to these sites triggers a series of conformational changes that lead to ATP binding and phosphorylation of Asp351. The energy from ATP hydrolysis is used to drive the translocation of Ca²⁺ against a concentration gradient, with the stoichiometry of 2 Ca²⁺ transported per ATP hydrolyzed [11]. The structure/function analysis of the Ca²⁺ binding and translocation domain has revealed that mutations affecting residues involved in Ca²⁺ coordination can severely impair pump function. For example, the Pro789Leu mutation, associated with Brody disease, is located in the M6 transmembrane helix and disrupts the packing of the transmembrane helices, reducing the stability and activity of the pump [12]. Similarly, mutations at Gly211 and Gly286, identified in Romagnola cattle with congenital pseudomyotonia, affect the A domain and the first transmembrane helix, respectively, leading to reduced protein stability and premature degradation [1]. ### 2.3 Conformational States and the Catalytic Cycle The SERCA1 catalytic cycle (often referred to as the Post-Albers cycle) involves transitions between two main conformational states: E1 (high Ca²⁺ affinity, cytoplasmic-facing) and E2 (low Ca²⁺ affinity, lumenal-facing). The cycle proceeds through the following steps: 1. **E1 state**: Two Ca²⁺ ions bind to the high-affinity sites from the cytoplasmic side. 2. **E1~P state**: ATP binds to the N domain and transfers a phosphate group to Asp351, forming a phosphoenzyme intermediate. 3. **E2-P state**: The conformational change occludes the Ca²⁺ ions and opens the lumenal gate, releasing Ca²⁺ into the SR lumen. 4. **E2 state**: Dephosphorylation occurs, and the pump returns to the E1 conformation, ready for another cycle. Crystal structures of the E2·MgF₄²⁻ state (1SU4) and the E1·Ca²⁺ state (1T5S) have provided detailed snapshots of these conformational states, revealing the domain movements that couple ATP hydrolysis to ion transport. The A domain rotates by approximately 30° during the E1 to E2 transition, while the N domain moves by up to 50° relative to the P domain. These large-scale movements are essential for the vectorial transport of Ca²⁺ across the membrane. ### 2.4 Interactive 3D Visualization For a comprehensive exploration of the SERCA1 three-dimensional structure, including the spatial arrangement of catalytic residues, Ca²⁺ binding sites, and conformational states, the interactive visualizer provides a user-friendly interface for structural analysis. [Interactive 3D Protein Visualizer: Load ATP2A1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14983) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Excitation-Contraction-Relaxation Coupling in Skeletal Muscle The primary physiological function of SERCA1 is to mediate muscle relaxation by re-sequestering cytosolic Ca²⁺ into the SR lumen. During excitation-contraction coupling, an action potential propagates along the T-tubule system and triggers the release of Ca²⁺ from the SR through the ryanodine receptor (RyR1). The released Ca²⁺ binds to troponin C, initiating the cross-bridge cycle and muscle contraction. Relaxation occurs when SERCA1 pumps Ca²⁺ back into the SR, reducing cytosolic Ca²⁺ concentration and allowing troponin to return to its resting state [2, 3]. The activity of SERCA1 is regulated by the small transmembrane protein sarcolipin (SLN), which binds to SERCA1 and reduces its apparent Ca²⁺ affinity, thereby modulating the rate of muscle relaxation. In horse gluteal muscle, which is composed predominantly of fast-twitch fibers, sarcolipin exhibits abundant RNA transcription but minimal protein expression, resulting in enhanced SR calcium transport capacity [4, 5]. This species-specific regulation highlights the importance of SERCA1-sarcolipin interactions in determining muscle performance and susceptibility to exertional rhabdomyolysis. ### 3.2 Calcium Homeostasis and Cellular Signaling Beyond its role in muscle contraction, SERCA1 contributes to the maintenance of intracellular Ca²⁺ homeostasis, which is critical for numerous cellular processes, including gene expression, apoptosis, and metabolism. The SERCA pumps (ATP2A1-3) are essential for maintaining low cytosolic Ca²⁺ concentrations (~100 nM) against the much higher concentrations in the SR/ER lumen (~1 mM) [6]. Disruption of SERCA function leads to ER stress, activation of the unfolded protein response (UPR), and altered cell survival signaling. In cancer cells, the expression and function of SERCA pumps are frequently altered, contributing to the rewiring of Ca²⁺ signaling that supports tumor growth and metastasis. Differential expression of SERCA genes has been documented in breast cancer cells, with ATP2A3 (SERCA3) playing a particularly important role in the anticancer activity of resveratrol [7, 8, 9]. While ATP2A1 is less commonly implicated in cancer than ATP2A3, its expression has been detected in certain tumor types, and its role in cancer biology is an area of active investigation. ### 3.3 Protein-Protein Interactions and Regulatory Networks SERCA1 interacts with a network of proteins that modulate its activity, stability, and subcellular localization. Key interaction partners include: - **Sarcolipin (SLN)**: A 31-amino acid proteolipid that inhibits SERCA1 activity by reducing its apparent Ca²⁺ affinity [10]. - **Phospholamban (PLN)**: Primarily regulates SERCA2 in cardiac muscle but can also interact with SERCA1 under certain conditions. - **HSC70/HSP70 chaperones**: Assist in the folding and quality control of SERCA1, preventing the accumulation of misfolded protein [11]. - **Ubiquitin-proteasome system components**: Mediate the degradation of misfolded or mutant SERCA1 proteins, as demonstrated in Chianina cattle pseudomyotonia [11]. The interaction between SERCA1 and the ubiquitin-proteasome system is particularly relevant to disease pathogenesis. In Chianina cattle with congenital pseudomyotonia, the mutant SERCA1 protein (Arg164Trp) is functional but misfolded, leading to its premature degradation by the ubiquitin-proteasome system. Inhibition of the proteasome with MG132 restores SERCA1 protein levels and calcium homeostasis in cellular models and muscle fibers, suggesting a potential therapeutic strategy for Brody disease [11]. ### 3.4 Transcriptional Regulation and Fiber-Type Specificity The expression of ATP2A1 is tightly regulated to maintain the fast-twitch phenotype of type II muscle fibers. The transcription factors MyoD, Ebf, and Six1 cooperate to activate ATP2A1 transcription, while the co-repressor HDAC4 can silence the gene in slow-twitch fibers [6, 9, 10]. The signaling pathways that control fiber-type specification, including the calcineurin/NFAT pathway and the PGC-1α pathway, also influence ATP2A1 expression. Aerobic exercise induces transcriptional responses that vary by muscle fiber type, with fast-twitch fibers showing distinct patterns of ATP2A1 regulation compared to slow-twitch fibers [12]. ```mermaid sequenceDiagram participant AP as "Action Potential" participant DHPR as "Dihydropyridine Receptor" participant RyR as "Ryanodine Receptor (RyR1)" participant SR as "Sarcoplasmic Reticulum" participant SERCA as "SERCA1 (ATP2A1)" participant Myo as "Myofilaments" AP->>DHPR: Depolarization of T-tubule DHPR->>RyR: Conformational coupling RyR->>SR: Ca²⁺ release SR->>Myo: Ca²⁺ binds troponin C Myo->>Myo: Cross-bridge cycling (contraction) Myo->>SERCA: Ca²⁺ re-uptake signal SERCA->>SR: ATP-dependent Ca²⁺ transport SR->>SR: Ca²⁺ storage (relaxation) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Brody Disease: Clinical Features and Genetic Basis Brody disease (OMIM #601003) is a rare autosomal recessive myopathy caused by pathogenic variants in ATP2A1. The condition was first described by Brody in 1969 and is characterized by exercise-induced muscle stiffness and delayed relaxation, particularly affecting the proximal limbs. Patients typically present in childhood or adolescence with difficulty running, abnormal gait, and muscle cramps that resolve with rest [1, 2, 3]. The stiffness is painless and not associated with electrical myotonia, distinguishing it from myotonic disorders [4]. The clinical spectrum of Brody disease is broad, ranging from mild exercise intolerance to severe functional impairment. In a large international cohort of 40 patients, the most common presenting symptoms were exercise-induced stiffness (100%), difficulty running (70%), and myalgia (45%) [3]. Muscle biopsy typically shows nonspecific changes, including fiber size variability and occasional tubular aggregates. Biochemical analysis reveals reduced SERCA1 protein expression and/or activity in muscle homogenates [2, 5, 6]. ### 4.2 Mutational Spectrum and Genotype-Phenotype Correlations More than 30 pathogenic variants in ATP2A1 have been reported in Brody disease patients, including missense, nonsense, frameshift, and splice-site mutations [3, 7, 12]. The mutations are distributed throughout the gene, with no single mutational hotspot. However, certain residues appear to be recurrently affected, suggesting functional importance: | **Mutation** | **Protein Change** | **Domain** | **Clinical Phenotype** | **Reference** | |---|---|---|---|---| | c.2366C>T | Pro789Leu | M6 transmembrane | Brody disease; reduced pump activity | [12] | | c.490C>T | Arg164Trp | A domain | Congenital pseudomyotonia (Chianina cattle) | [8] | | c.632G>T | Gly211Val | A domain | Congenital pseudomyotonia (Romagnola cattle) | [1] | | c.857G>T | Gly286Val | M1 transmembrane | Congenital pseudomyotonia (Romagnola cattle) | [1] | | c.1222A>G | Asn408Asp | N domain | Brody disease; reduced ATP binding | [7] | | c.1843C>T | Arg615Trp | P domain | Brody disease; impaired phosphorylation | [3] | The Pro789Leu mutation, identified in a patient with Brody disease, reduces SERCA1 activity by approximately 50% when expressed in heterologous systems [12]. Structural modeling suggests that the substitution of proline with leucine disrupts the packing of the M6 helix, destabilizing the transmembrane domain and impairing Ca²⁺ translocation. Similarly, the Arg164Trp mutation in Chianina cattle causes misfolding of the A domain, leading to recognition by the quality control machinery and degradation via the ubiquitin-proteasome pathway [8, 11]. ### 4.3 Congenital Pseudomyotonia in Cattle: A Large-Animal Model Congenital pseudomyotonia (PMT) in cattle is a naturally occurring animal model of Brody disease, caused by mutations in the bovine ATP2A1 gene. The condition has been described in several breeds, including Chianina, Romagnola, and Dutch Improved Red and White cross-breed cattle [1, 8, 9, 10, 11, 12]. Affected calves present with exercise-induced muscle stiffness, delayed relaxation, and an abnormal gait, closely resembling the human phenotype. The Chianina PMT is caused by a missense mutation (Arg164Trp) that leads to the production of a misfolded but partially functional SERCA1 protein. The mutant protein is retained in the endoplasmic reticulum and targeted for degradation by the ubiquitin-proteasome system, resulting in a severe reduction in SERCA1 protein levels in fast-twitch muscle fibers [8, 11]. Interestingly, the residual SERCA1 activity is sufficient to maintain basal calcium homeostasis but inadequate for the demands of high-frequency muscle contraction. In Romagnola cattle, two distinct mutations (Gly211Val and Gly286Val) have been identified, each causing a similar phenotype but with different molecular consequences [1]. The Gly211Val mutation affects the A domain and reduces protein stability, while the Gly286Val mutation affects the M1 transmembrane helix and impairs Ca²⁺ binding. These genotype-phenotype correlations provide valuable insights into the structure-function relationships of SERCA1. ### 4.4 Brody Syndrome and Differential Diagnosis Brody syndrome is a term used to describe patients with clinical features resembling Brody disease but without identifiable mutations in ATP2A1. These patients may have reduced SERCA1 protein expression or activity due to secondary causes, such as altered gene regulation or post-translational modifications [4, 5]. The distinction between Brody disease and Brody syndrome is important for genetic counseling and prognostic purposes. The differential diagnosis of Brody disease includes other causes of exercise-induced muscle stiffness, such as myotonia congenita (CLCN1 mutations), paramyotonia congenita (SCN4A mutations), and myotonic dystrophy (DMPK or CNBP expansions). Brody disease is distinguished by the absence of electrical myotonia on electromyography and the presence of normal muscle relaxation at rest [1, 4]. Repetitive nerve stimulation studies may show a pseudo-increment pattern, which can aid in diagnosis [1]. ### 4.5 Zebrafish Models and Dominant Mutations The zebrafish (Danio rerio) has emerged as a valuable model for studying ATP2A1 function and Brody disease pathogenesis. The "accordion" mutant, which exhibits sustained bilateral trunk muscle contractions, carries a dominant mutation in atp2a1/SERCA1 [2, 3]. This mutant displays abnormal muscle relaxation and serves as a model for the human condition. The dominant nature of the zebrafish mutation contrasts with the recessive inheritance pattern observed in humans, suggesting that certain mutations may exert dominant-negative effects. The accordion mutant has been used to evaluate novel pharmaceutical approaches for Brody disease. Treatment with the CFTR corrector C17, which was originally developed for cystic fibrosis, has been shown to rescue defective SERCA1 in bovine pseudomyotonia and may represent a potential therapy for Brody myopathy [4, 5]. These preclinical studies highlight the translational potential of animal models in developing targeted therapies. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Brucella abortus and Macrophage Calcium Signaling Recent research has revealed an unexpected role for ATP2A1 in host-pathogen interactions. Infection of macrophages with Brucella abortus, the causative agent of brucellosis, leads to alterations in ATP2A1 expression and calcium signaling [6]. The bacterial outer membrane protein Omp19 induces an inflammatory response in macrophages that is modulated by ATP2A1, which regulates cell adhesion and calcium signaling pathways. Treatment with Codonopsis pilosula polysaccharide (CPPS) attenuates the inflammatory response by modulating ATP2A1 expression, suggesting that targeting ATP2A1 could be a therapeutic strategy for brucellosis. The mechanism by which Brucella exploits ATP2A1 involves the manipulation of host calcium homeostasis to create a permissive environment for bacterial survival and replication. By altering SERCA1 expression, the bacteria can modulate cytosolic Ca²⁺ levels, affecting downstream signaling pathways involved in the immune response. This interaction highlights the broader role of calcium pumps in host defense and pathogen evasion. ### 5.2 Viral Interactions and Myotonic Dystrophy While direct viral interactions with ATP2A1 are not well-documented, the gene is affected in myotonic dystrophy type 1 (DM1), a condition that can be triggered or exacerbated by viral infections. The expanded CUG repeats in the DMPK gene sequester MBNL1, leading to mis-splicing of ATP2A1 and other muscle genes [7, 8]. Viral infections that increase cellular stress or alter RNA-binding protein activity could potentially exacerbate this mis-splicing, contributing to the muscle symptoms of DM1. The equine form of myotonic dystrophy (eMD) shares clinical and histopathological features with human DM1, including aberrant skeletal muscle morphogenesis and myofiber differentiation [8]. While the genetic basis of eMD is not fully understood, alterations in ATP2A1 expression and splicing may contribute to the phenotype. Comparative studies between human and equine myotonic dystrophy could provide insights into the molecular mechanisms underlying these disorders. ### 5.3 Environmental Toxicants and ATP2A1 Expression Exposure to environmental toxicants has been shown to affect ATP2A1 expression in various model organisms. Waterborne benzo[a]pyrene (B[a]P) exposure disrupts the normal locomotor behavior of adult zebrafish and alters the expression of genes involved in muscle function, including atp2a1 [9]. Similarly, silver nanocolloids and zinc oxide nanoparticles have been shown to disrupt medaka embryogenesis through effects on vital gene expressions, potentially including calcium-handling genes [10, 11]. These findings suggest that environmental pollutants can interfere with calcium homeostasis and muscle function through effects on ATP2A1. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Current Therapeutic Landscape There are currently no FDA-approved drugs specifically targeting ATP2A1 for the treatment of Brody disease. Management of the condition is primarily supportive, focusing on symptom relief and avoidance of triggering factors. Physical therapy, stretching exercises, and lifestyle modifications may help alleviate muscle stiffness. In severe cases, pharmacological agents that modulate calcium handling, such as dantrolene (a RyR1 inhibitor), have been used empirically, although their efficacy is variable. ### 6.2 Investigational Therapies and Drug Repurposing Several investigational approaches are being explored for the treatment of Brody disease and related conditions: - **CFTR corrector C17**: Originally developed for cystic fibrosis, C17 has been shown to rescue defective SERCA1 in bovine pseudomyotonia by promoting proper protein folding and trafficking [4]. This drug repurposing strategy holds promise for Brody disease patients with misfolding mutations. - **Proteasome inhibitors**: MG132 and other proteasome inhibitors can restore SERCA1 protein levels in cellular models of pseudomyotonia by preventing the degradation of misfolded but functional protein [11]. However, the systemic toxicity of proteasome inhibitors limits their clinical application. - **Small-molecule splicing modulators**: Compounds that rescue mis-splicing of ATP2A1 in DM1, such as dimeric 1,3-diaminoisoquinoline derivatives, are being investigated as potential therapies [7]. These agents target the RNA-protein interactions that underlie the splicing defect. - **Gene therapy**: Adeno-associated virus (AAV)-mediated delivery of a functional ATP2A1 cDNA is a theoretical approach for replacing the defective gene. While no clinical trials have been initiated, preclinical studies in animal models would be a necessary first step. ### 6.3 ATP2A1 as a Drug Target in Other Diseases Beyond Brody disease, ATP2A1 is being explored as a therapeutic target in other conditions: - **Cancer**: The differential expression of SERCA genes in cancer cells has led to interest in targeting SERCA pumps for anticancer therapy. While most attention has focused on ATP2A3, ATP2A1 may also play a role in certain tumor types [8, 9]. SERCA inhibitors, such as thapsigargin and its derivatives, have been shown to induce apoptosis in cancer cells by depleting ER calcium stores. - **Metabolic syndrome**: SERCA pumps are key regulators of calcium handling in vascular smooth muscle cells, and their dysfunction contributes to the pathophysiology of metabolic syndrome [12]. Modulating SERCA1 activity could potentially improve vascular function in this context. - **Cognitive disorders**: Genome-wide association studies have identified ATP2A1 as a candidate gene for cognitive abilities, and Mendelian randomization analyses suggest that ATP2A1 expression may be a therapeutic target for cognitive performance [1, 2, 3]. The mechanism underlying this association is unclear but may involve calcium signaling in neurons. ### 6.4 Pharmacogenomic Considerations Genetic variation in ATP2A1 may influence individual responses to drugs that affect calcium handling. For example, patients with Brody disease may be more sensitive to the effects of volatile anesthetics, which can trigger malignant hyperthermia in susceptible individuals. Genetic panel testing for malignant hyperthermia has identified variants in RYR1 and CACNA1S as major susceptibility genes, but the role of ATP2A1 variants in this context is less clear [4]. Pharmacogenomic testing for ATP2A1 variants could help identify patients at risk for adverse drug reactions. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for ATP2A1 research: | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | NCBI Gene | 487 | Gene ID for human ATP2A1 | | Ensembl | ENSG00000196296 | Gene annotation and transcript variants | | UniProt | O14983 | Protein sequence and functional annotation | | RCSB PDB | 1SU4, 1T5S, 2OA0, 3AR4, 4H1B | Crystal structures of SERCA1 in different conformations | | OMIM | 601003 | Brody disease; ATP2A1 gene entry | | ClinVar | Various | Pathogenic variants and clinical classifications | | Gene Ontology (GO) | GO:0005388 (Ca²⁺:H⁺ antiporter activity); GO:0006816 (calcium ion transport); GO:0005886 (plasma membrane) | Functional annotations | | STRING | 9606.ENSP00000356150 | Protein-protein interaction network | | BioGRID | 112233 | Physical and genetic interactions | | GTEx Portal | ATP2A1 | Tissue-specific expression data | | Human Protein Atlas | ENSG00000196296 | Protein expression and localization | --- ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway) ## References [1] Rombouts, T., Druet, T., Duarte, J., Ahariz, N., Karim, K., Coppieters, W., Smet, S. D., Georges, M., & Charlier, C. (2022). A hypomorphic mutation in the ATP2A1 gene increases muscle mass yet compromises meat quality of Belgian Blue cattle. Scientific Publication. https://www.semanticscholar.org/paper/26be3aba2a2be67ca640cfb1984f8f5044b6f115 [2] Rombouts, T., Druet, T., Gualdrón Duarte, J., Ahariz, N., Karim, K., Coppieters, W., Smet, S. D., Georges, M., & Charlier, C. (2022). 634. A hypomorphic mutation in the ATP2A1 gene increases muscle mass yet compromises meat quality of Belgian Blue cattle. Proceeding of 12th World Congress on Genetics Applied to Livestock Production (WCGALP). https://www.semanticscholar.org/paper/cf098a6a877883c121a10f05319df08d4ab9aa75 [3] Drögemüller, C., Drögemüller, M., Leeb, T., Mascarello, F., Testoni, S., Rossi, M., Gentile, A., Damiani, E., & Sacchetto, R. (2008). Identification of a missense mutation in the bovine ATP2A1 gene in congenital pseudomyotonia of Chianina cattle: an animal model of human Brody disease. Genomics. https://www.semanticscholar.org/paper/6027a83942a789b4ed57c3dfd8d20867a5d75c7a [4] Pan, Y., Zvaritch, E., Tupling, A. R., Rice, W. J., de Leon, S., Rudnicki, M., McKerlie, C., Banwell, B., & Maclennan, D. (2003). Targeted Disruption of the ATP2A1 Gene Encoding the Sarco(endo)plasmic Reticulum Ca2+ ATPase Isoform 1 (SERCA1) Impairs Diaphragm Function and Is Lethal in Neonatal Mice. Journal of Biological Chemistry. https://www.semanticscholar.org/paper/99ce2ec57aaaa5de80c930262dfc958f4871e69b [5] Maclennan, D., Rice, W., & Odermatt, A. (1997). Structure/Function Analysis of the Ca2+ Binding and Translocation Domain of SERCA1 and the Role in Brody Disease of the ATP2A1 Gene Encoding SERCA1 a. Annals of the New York Academy of Sciences. https://www.semanticscholar.org/paper/c3e6b93f341d0894d9dccefa1fb922b818cb8ef4 [6] Ciobanu, D., Zhang, Y., & Rothschild, M. (2002). Rapid communication: mapping of the Ca2+ ATPase of fast twitch 1 skeletal muscle sarcoplasmic reticulum (ATP2A1) gene to porcine chromosome 3. Journal of Animal Science. https://www.semanticscholar.org/paper/96089b3daff6ff4888a821661a98a4865705ad28 [7] Sternberg, D., Chevessier, F., Bassez, G., Béhin, A., Echaniz-Laguna, J. A., Eymard, B., Franques, J., Péréon, Y., Vicart, S., Fontaine, B., Hantai, B., & Fournier, F. (2011). Brody syndrome represents a differential diagnosis for painless exercise-induced stiffness without electrical myotonia: detection of 10 cases associated with mutations in ATP2A1 gene. Scientific Publication. https://www.semanticscholar.org/paper/9906712403c0a0bc42d03653f19d5411a3fa82cb [8] Matsumoto, J., Nakamori, M., Okamoto, T., Murata, A., Dohno, C., & Nakatani, K. (2020). The Dimeric Form of 1,3‐Diaminoisoquinoline Derivative Rescued the Mis‐splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Type 1 Mouse Model. Chemistry. https://www.semanticscholar.org/paper/1e10a1a8f55e25771f9a5549cab3199874675b35 [9] Grünberg, W., Sacchetto, R., Wijnberg, I., Neijenhuis, K., Mascarello, F., Damiani, E., & Drögemüller, C. (2010). Pseudomyotonia, a muscle function disorder associated with an inherited ATP2A1 (SERCA1) defect in a Dutch Improved Red and White cross-breed calf. Neuromuscular Disorders. https://www.semanticscholar.org/paper/a80991b05ec9aa726762e97ebba134a2bb413973 [10] Olson, B., Sgourdou, P., & Downes, G. B. (2010). Analysis Of A Zebrafish Behavioral Mutant Reveals A Dominant Mutation In atp2a1/SERCA1. Genesis. https://www.semanticscholar.org/paper/7402a1e814464178484ff3dda56b32e070f06c4f [11] Dranchak, P. K., Valberg, S., Onan, G., Gallant, E., Binns, M., Swinburne, J., & Mickelson, J. (2006). Exclusion of linkage of the RYR1, CACNA1S, and ATP2A1 genes to recurrent exertional rhabdomyolysis in Thoroughbreds. American Journal of Veterinary Research. https://www.semanticscholar.org/paper/eef6812ea30cb89447d8a299dbb8b20994b3698e [12] Yalcin, S., Şahin, K., Tuzcu, M., Bilgen, G., Özkan, S